Comparative study between Midazolam and dexmedetomidine nebulisation in a patient posted for fiberoptic bronchoscopy

Midazolam vs dexmedetomidine nebulization as adjuvant to lignocaine a comparative study during awake flexible fiberoptic bronchoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052514

Enrollment

Registered

2023-05-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J709- Respiratory conditions due to unspecified external agent

Interventions

Intervention1: Nebulized with mixture of 4% lignocaine 4 ml and midazolam 0.2mg/kg by using ultrasonic nebulizer followed by FFB: Group I : patient will be nebulized with mixture of 4% lignocaine 4 ml

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 to 60 years ASA I/II Scheduled for elective bronchoscopy procedure(Diagnostic & therapeutic)

Exclusion criteria

Exclusion criteria: Unconscious and uncooperative patients Intubated patient on ventilator, patient need general anaesthesia Patient on oxygen Asthmatics Epileptics Coagulation abnormalities

Design outcomes

Primary

Measure	Time frame
To determine mean cough scoreTimepoint: 30 min	—

Secondary

Measure	Time frame
Gag reflex patient comfort post procedure patient satisfaction Ramsay sedation score (RSS) signs of lignocaine toxicity Timepoint: 1 hour	—

Countries

India

Contacts

Public ContactPoonam Kumari

All India Institute of Medical Sciences,Patna

drpoonam1981@gmail.com9473199126

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026